The Thesis
Abbott Laboratories is a healthcare giant that earns money by selling a mix of medical devices, diagnostic tests, nutrition products, and branded medicines. The company generated $41.95 billion in revenue last year, growing nearly 5% as it successfully moved past the volatility of the pandemic. The transition from a provider of emergency COVID tests to a leader in chronic disease management marks the structural shift that makes the current growth story possible.
What makes this work boils down to a few specific things.
In our view, the market is significantly underestimating the earnings power of the medical device business. The stock currently trades at a discount to its historical average despite owning a leading position in the world's most successful glucose monitor. We think Abbott is one of the cleaner ways to own the aging-population theme without the binary risks of a traditional drug company. The case only strengthens if the company can prove that its new heart valves and rhythm devices are capturing market share from legacy competitors.
Numbers at a Glance
What does it do?
Abbott Laboratories is a mature business that earns money by selling life-critical healthcare products across four distinct segments. The company makes money through high-volume sales of medical hardware like heart valves and glucose monitors, recurring revenue from diagnostic lab chemicals, and retail sales of infant formula and adult nutrition shakes. The medical device arm operates on a razor-and-blade model: once a patient uses an Abbott heart valve or a glucose sensor, the company secures long-term revenue through replacement parts or ongoing monitoring.
Where does revenue come from?
Medical devices and diagnostics generate the majority of sales, followed by nutritional products and generic medicines sold in emerging markets. The Medical Devices segment provides about 40% of revenue, while Diagnostics and Nutrition each contribute roughly 25%. Geographically, Abbott is a global operation with about 60% of its sales coming from outside the United States.
Revenue Breakdown
Revenue by Geography
Who are its customers?
Abbott Laboratories serves millions of individual patients, hospital systems, diagnostic laboratories, and retail consumers. The company's FreeStyle Libre system alone serves millions of diabetic patients globally, generating over $5 billion in annual sales. Its diagnostics segment supports thousands of hospital labs that rely on Abbott equipment for routine blood work and specialized testing. In the nutrition segment, the company sells to parents and seniors through pharmacies and grocery stores, maintaining leading market share with brands like Similac and Ensure.
What gives it staying power?
Abbott has staying power because its products are deeply embedded in hospital workflows and patient daily lives. High switching costs in diagnostic labs and a massive patent portfolio in medical devices create a wide moat. Once a lab installs Abbott's testing machines, the cost and training required to switch to a competitor are prohibitive.
Where is it headed?
Management is betting heavily on the convergence of consumer technology and medical data. The goal is to turn the FreeStyle Libre platform into a broader health sensor that can monitor more than just sugar levels. If successful, this would move Abbott from being a device seller to being a vital data provider for chronic disease management.
Abbott has successfully navigated the post-pandemic cliff as its core medical device business now more than offsets the loss of COVID testing revenue. Revenue reached $41.95 billion in 2024, proving that the underlying growth in heart health and diabetes is durable.
Cash generation remains a hallmark of the business with free cash flow of $6.35 billion in 2024. This cash consistently tracks net income, showing that the earnings the company reports are backed by actual money in the bank.
The balance sheet is conservatively managed with a debt-to-equity ratio of 0.65x and ample cash reserves. This financial strength allows the company to continue its 52-year streak of dividend increases while still spending billions on new product research.
Abbott is a financially resilient compounder that has proven it can grow through multiple different economic and health cycles.
Medical device growth is accelerating, led by the FreeStyle Libre system which is now growing at a double-digit rate. This high-margin segment is becoming a larger portion of the total company, which naturally pulls up overall profitability. Management is also seeing a strong recovery in routine diagnostic testing as hospital procedures return to normal levels.
The single most important risk is the legal environment surrounding the infant formula business. Legal challenges regarding specialized formula for premature infants could lead to significant settlements or reputational damage. While management is defending these cases vigorously, the ultimate financial impact remains a variable that could weigh on the stock.
The global medical technology and diagnostics market is roughly $550 billion today and is growing at a steady 5% annually, putting it on track to exceed $700 billion by 2030. This is an exceptionally high-quality industry because products are often medically necessary and protected by complex regulatory barriers that prevent new competition. Pricing power is structural because hospitals prioritize reliability and patient outcomes over minor price differences. Abbott is a clear leader in this market, holding the top spot in continuous glucose monitoring and a dominant position in diagnostic testing.
The medical device market is rationally structured among a few massive players that compete on innovation rather than price. Barriers to entry are enormous because gaining FDA approval and building a global sales force takes decades and billions of dollars. This structure protects the long-term profit margins of the leaders.
Abbott faces its toughest challenge in the diabetes space from Dexcom(DXCM), which focuses solely on glucose monitoring and often beats Abbott to market with new software features. In the heart market, Medtronic(MDT) uses its massive scale to bundle different surgical products together, making it harder for Abbott to win individual contracts. The most dangerous threat is Dexcom, which is currently fighting Abbott for the millions of type 2 diabetes patients just beginning to use monitoring technology.
Abbott is currently holding its ground and gaining share in the diabetes market specifically. FreeStyle Libre sales grew over 14% in the most recent results, outpacing many smaller rivals.
Abbott's widest moat comes from the high switching costs embedded in its diagnostic laboratory systems. Once a hospital installs Abbott's Alinity testing platform, they are locked into using Abbott's proprietary chemicals and software for years. This creates a recurring revenue stream that is nearly impossible for competitors to disrupt without a multi-year replacement cycle.
The company's 56.4% gross margin and 52-year dividend streak prove that this is not just a good cycle, but a structurally protected business. These numbers confirm that Abbott can maintain high prices and consistent cash flow even when the broader economy is struggling.
Abbott's moat is strengthening as it integrates AI into its diagnostics and expands the Libre platform into a broader health ecosystem.
Navigated 90% drop in COVID testing revenue while keeping total company revenue growing.
Maintained 52-year dividend growth streak while funding $4B+ in annual R&D.
CEO Robert Ford holds a personal stake valued well over $100 million.
Capital Allocation Track Record
Robert Ford has proven to be a steady and effective leader by managing the extreme volatility of the pandemic. He successfully used the cash windfall from COVID tests to pay down debt and reinvest in the core medical device business. The company's ability to grow earnings despite losing billions in diagnostic testing revenue is a testament to management's long-term planning. We trust this team to continue their disciplined approach to both dividends and innovation.
© 2026 ClearThesis.ai · Report generated on May 28, 2026
This is an AI-generated analysis for informational purposes only and does not constitute financial advice. Data and analysis may not reflect recent developments if viewed significantly after the generation date. Always conduct your own due diligence before making any investment decisions.